Clinical Efficacy and Safety of Tumor Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer. (12th April 2023)

• Record Type: Journal Article
• Authors: Yu, Huapeng; Xu, Cuixia; Li, Qirong
• Other Names: Yang Xiaotong Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2023(2023)
• Publication Date: 2023-04-12
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2023/6412679
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Objective . To assess the clinical efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. Methods . From April 2018 to November 2021, 66 patients with ovarian cancer were admitted to our hospital and randomly allocated to undergo intravenous chemotherapy following CRS (the observation group) or CRS with HIPEC (the experimental group) using a parallel randomized technique, with 33 cases in each group. Clinical effectiveness, intraoperative and postoperative recovery, VEGF level, T-lymphocyte subpopulation cell level, adverse events, and patient survival were all outcome metrics. Results . CRS plus HIPEC was associated with significantly higher clinical efficacy versus CRS alone (P < 0.05 ). The difference in the intraoperative bleeding and operative time between the two groups did not meet the statistical standard (P > 0.05 ). Patients in the experimental group experienced shorter postoperative chemotherapy and length of hospital stay than those in the observation group (P < 0.05 ). CRS plus HIPEC resulted in significantly lower levels of VEGFA, VEGFB, and VEGFC and higher levels of CD3+, CD4+, and CD3+/CD4+ than CRS alone (P < 0.05 ). The two groups of patients had a similar incidence of adverse events (P > 0.05 ). The experimental group showed a longer median survival (25 months) and a 1-year survival rate (79.55%) than the observation group (22 months, 49.56%) (log rank = 20.411, P < 0.05 ). A significantly lower 1-year recurrence rate was observed in the experimental group than in the observation group (P < 0.05 ). Conclusion . CRS plus HIPEC effectively improves the clinical efficacy of ovarian cancer patients, prolongs the survival of patients, and improves the level of VEGF and T-lymphocyte subpopulation cells, with a manageable safety. In addition, the treatment method can improve the therapeutic effect, reduce the toxic and side effects, and improve the immunity of the body, which is worthy of clinical promotion.